IDEAYA Biosciences (NASDAQ:IDYA) stock surged 27% on Monday after the company reported encouraging topline results from its Phase 2/3 registrational study evaluating darovasertib in combination with ...

An M.D.-Ph.D. candidate in Georgetown University’s tumor biology program defended his dissertation, titled “Molecular Signatures of Treatment Responses in Tumors and Serial Liquid Biopsies in Patients ...

Duke Cancer Institute researchers have identified potential biomarkers that predict the likelihood for checkpoint inhibitor drugs to backfire, driving hyper-progression of melanoma cells instead of ...

Patients received an initial intratumoral injection of RP1 with up to 7 additional doses every 2 weeks, plus 240 mg nivolumab ...

Patients with advanced melanoma skin cancer survive for longer without their disease progressing if they have been treated with a combination of two drugs, nivolumab and ipilimumab, than with either ...

Flow cytometry effectively detects CTCs in melanoma patients, offering a rapid, cost-effective alternative to molecular biology. CTCs are present across all melanoma stages, with a significant ...

In the CheckMate 238 trial, patients with resected stage IIIB–C or stage IV melanoma who were treated with nivolumab had longer recurrence-free survival than those who received ipilimumab. Data were ...

Explore the latest statistics on cutaneous melanoma: why incidence rates are rising by 1.2% annually while mortality is ...